Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 7 of 33 · 1559 articles
If shorter, non-contrast MRE protocols can reliably show Crohn’s activity and strictures, patients could have faster scans with less gadolinium exposure. But if ulceration or penetrating disease is suspected,...
PSC co-occurring with celiac disease appears more common than expected and is associated with a high rate of liver complications (including cirrhosis) and frequent coexisting IBD—information that may affect monitoring...
People with IBD often hear about “treat-to-target” as a path to deeper healing.
Links between GWAS risk loci and the specific cell types where those loci may act can focus laboratory experiments and eventually help identify causal genes or pathways relevant to Crohn’s disease.
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Cureus.
This review explains how new drug classes and mechanism-focused strategies may change how IBD is treated, which could affect choices for patients who have not responded to existing therapies and inform discussions about...
The review suggests NETs are elevated in IBD and that reducing NETs activity helped in animal models—so NETs could be a future therapeutic target and a biomarker of disease severity.
The review proposes S100B as a molecular link connecting enteric glial activation, intestinal barrier dysfunction, and liver/brain inflammation. If confirmed, this could help explain symptom overlap between gut and...
The review compiles trial and real-world safety data for upadacitinib in IBD and highlights monitoring needs and infection risks (notably herpes zoster), which are directly relevant when choosing or managing JAK...
The work aims to improve colon-targeted delivery of an aminosalicylate (balsalazide) to boost local drug levels and protect the drug from gastric degradation—potentially relevant to people with ulcerative colitis looking...
Early, easily available blood markers that predict mucosal healing could help clinicians decide sooner whether a new or intensified therapy is working, potentially reducing prolonged ineffective treatment and guiding...
Researchers are testing a new swallowable thermal capsule that could eventually help detect temperature changes from GI inflammation. For people with Crohn’s disease or IBD, a safe, noninvasive way to sense inflammatory...
A minimally invasive probe that measures intestinal potential difference in real time could provide a localized, objective way to study gut barrier function—an important feature in Crohn’s disease and other IBDs....
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from Gastro hep advances.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Enzyme and Microbial...
Transition from paediatric to adult services is a high-risk period for gaps in care. Consensus recommendations aim to standardise pathways, support young people’s needs, and reduce barriers to effective treatment.
People with IBD who have failed multiple advanced therapies are often the most difficult to treat, yet this review shows they are under-represented in clinical trials. That limits direct evidence about how well new...
New biomarkers and cell-type insights could help future diagnostic tools or targeted therapies in UC by pointing to TRP channel–related genes and B/plasma cell involvement.
Standardised care pathways may reduce hospital admissions and help health systems manage the burden of IBD without worsening patient-reported disease control.
Patients with refractory IBD or those not fully responding to single targeted therapies may be interested because ACT aims to control multiple inflammatory pathways and could offer improved symptom and endoscopic...
If genetics helps explain who develops Crohn’s disease, better ways to pick the handful of important variants could speed discovery of biological mechanisms and future tests.
This report describes open‑label extension data for ontunisertib, an investigational oral drug being tested specifically for fibrostenosing Crohn’s disease.
Bright, round objects on stomach CT scans can be mistaken for retained pills or bleeding. For people with Crohn's disease who commonly receive CT enterography and may have bile reflux or duodenal narrowing, this report...
A colon-targeted delivery system could allow an anti-inflammatory plant extract (Myrica esculenta) to reach the colon with minimal systemic exposure, which may be relevant for developing localized treatments for...
CDI is a common and serious complication in people hospitalized with IBD. Understanding whether CDI independently increases the risk of death, ICU care, or surgery — or mainly drives longer stays and higher costs — helps...
Shortening ustekinumab dosing intervals raised drug levels and was associated with high rates of steroid-free clinical remission in this small prospective IBD cohort, offering a practical option for patients who lose...
If you have fibrostenosing Crohn’s disease, this investigational oral drug is being studied specifically for strictures — the company reports high CDAI remission in the extension and plans a larger randomized study...
This registry will collect real-world data on guselkumab use in adults with moderate-to-severe Crohn's disease or ulcerative colitis, focusing on how long patients stay on treatment, effectiveness in routine practice,...
This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the...
People with Crohn's disease often ask whether food additives and artificial sweeteners affect gut microbes or disease activity. This trial directly tests whether sucralose changes the fecal microbiome in adults with...
If gut microbes produce LPC/LPA that are linked to chronic abdominal pain, it could point to new biomarker or microbiome-targeted approaches for unexplained pain in IBD patients whose inflammation is quiet or minimal.
Patients with fibrostenosing Crohn’s disease have limited treatment options for the fibrotic strictures that can lead to procedures and surgery. These OLE findings suggest ontunisertib may be safe long-term and could...
Predicting which patients with acute severe ulcerative colitis will need colectomy or will not respond to steroids can guide early treatment decisions. This study shows that important predictors differ between East Asian...
If you or your child has pediatric-onset IBD, much of the care that supports disease management happens between scheduled visits. Recognizing this workload matters for access, clinician time, and policies that affect...
AI models are being developed to support IBD care (activity scoring, risk prediction), but most studies are retrospective and don’t yet demonstrate that AI outputs reliably change clinical decisions or improve outcomes....
Simpler patient-reported scores (PRO2/PRO3) were much more often available in routine clinic visits than CDAI or HBI, yet they agreed closely with those indices. That could make regular monitoring and telehealth...
A multimodal, simpler activity score could improve practical disease monitoring when full ileocolonoscopy isn’t possible and help standardize treat-to-target practice across centers.
Routinely collected healthcare data can reveal how Crohn’s disease is managed and experienced in everyday practice, helping fill gaps left by clinical trials. A broader, data-driven measure of disease burden could better...
Interstitial lung disease (ILD) is an underrecognized extraintestinal complication in IBD that in this study was relatively common (12%) and associated with a substantially increased risk of death.
A validated prediction score that reliably rules out clinically significant CT findings could reduce unnecessary CT imaging, radiation exposure, and costs for people with Crohn's disease experiencing acute symptoms.
Circulating glycoprotein signals may help explain how systemic inflammation in IBD interacts with metabolic liver disease (MASLD). If validated, they could improve risk stratification for liver complications beyond...
Organoid models aim to reproduce human intestinal biology more closely than traditional cell lines or animal models, which could improve understanding of IBD mechanisms and help develop or personalize therapies.
A microbiome-targeted, food-grade supplement could offer a non-immunosuppressive option for people with mild-to-moderate ulcerative colitis who remain inflamed or want to delay immunosuppressive/biologic therapy. The...
IUS offers a rapid, radiation-free way to detect active inflammation and common complications in IBD, which could improve initial ED assessment and reduce reliance on CT scans.
The work suggests specific host genes and cell types that might mediate links between gut microbes and IBD, which could direct future laboratory research into mechanisms and potential biomarkers.
Shorter hospital stay after colorectal surgery can reduce disruption, infection risk, and costs. This review suggests ERAS pathways can shorten length of stay for people with IBD without increasing short-term...
This case series points to risankizumab as a potential option for children with IBD who have failed multiple biologics, and it reports use of noninvasive monitoring like intestinal ultrasound.
The article reports a new oral nanozyme that combines imaging and ROS-scavenging therapy aimed at IBD lesions—an early-stage approach that could one day enable targeted, noninvasive treatment and lesion tracking.
